Ironwood Pharmaceuticals (IRWD) Common Equity (2009 - 2026)

Ironwood Pharmaceuticals has disclosed Common Equity across 18 years of filings, most recently posting -$217.1 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$217.1 million, up 35.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$217.1 million (up 35.0% YoY), and the FY2025 annual result was -$261.8 million, up 13.11% from the prior year.
• Common Equity came in at -$217.1 million for Q1 2026 at Ironwood Pharmaceuticals, up from -$261.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $706.9 million in Q1 2023 to a low of -$346.8 million in Q2 2023.
• The 5-year median for Common Equity is -$301.3 million (2024), against an average of -$39.3 million.
• Across the five-year window, Common Equity surged 369.89% in 2022 and slumped 165.08% in 2023, its largest moves.
• Ironwood Pharmaceuticals' Common Equity stood at $652.4 million in 2022, then sank by 153.08% to -$346.3 million in 2023, then rose by 12.98% to -$301.3 million in 2024, then climbed by 13.11% to -$261.8 million in 2025, then climbed by 17.07% to -$217.1 million in 2026.
• The last three Common Equity figures came in at -$217.1 million (Q1 2026), -$261.8 million (Q4 2025), and -$264.2 million (Q3 2025), per Business Quant data.